Skip to main content
Clinical Trials/NCT05051670
NCT05051670
Completed
Not Applicable

The Safety and Feasibility of Reduced Port Robotic Distal Gastrectomy Using da Vinci SP for Early Gastric Cancer

Yonsei University1 site in 1 country19 target enrollmentDecember 16, 2021
ConditionsGastric Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gastric Cancer
Sponsor
Yonsei University
Enrollment
19
Locations
1
Primary Endpoint
major complication
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Laparoscopic surgery revolutionized the surgical treatment of gastric cancer saving large incsion and associated pain. Robotic surgical system was introduced to enhance the minimally invasive surgery using articulating robotic arm. The da vinci SP system, which enables single-port surgery, can allow surgeon to provide radical gastrectomy with minimal scar and associated pain.

Detailed Description

This study is a phase 1/2, single-arm surgical clinical trial. The primary endpoint is the safety of da vinci robotic gastrectomy. The secondary endpoint is operative time, bleeding, bowel recovery, and hospital stay. In the clinic, informed consent is received from patient who is scheduled to undergo radical gastrectomy. After the general anesthesia, low midline transverse incision is made at suprapubic area. After inserting SP port into the peritoneal cavity, additional port is inserted via right flank that would be used for assistant's energy device and suction devices. Radical subtotal gastrectomy is perfromed using cardiere-forceps, monopolar scissors, and maryland forceps. Reconstruction after gastrectomy is decided according to surgeon's preference. three days after gastrectomy, if the diet build up is complete and the patients has no evidence of complication, the patient is discharged from the hospital. Four weeks after gastrectomy, the patient will be followed up at the clinic. Major complication event within 30days after gastrectomy will be analyzed as primary endpoint as well as other secondary endpoints.

Registry
clinicaltrials.gov
Start Date
December 16, 2021
End Date
December 11, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Biopsy confirmed adenocarcinoma of stomach scheduled to undergo radical gastrectomy
  • Between 20-80
  • ASA score (American society of anesthesiology) class: I - III
  • Signed to informed consent after through explanation about the study

Exclusion Criteria

  • distant metastasis
  • EMR/ESD canddiate
  • complicated gastric cancer (obstruction or perforation)
  • Active other primary tumor
  • Vulerable subject (illiterate, pregnant)

Outcomes

Primary Outcomes

major complication

Time Frame: 30 days after gastrectomy

Clavien-Dindo classification grade 3 or more

Secondary Outcomes

  • Operation time(30 days after gastrectomy)
  • bleeding(30 days after gastrectomy)
  • bowel recovery(30 days after gastrectomy)
  • Hospital stay(30 days after gastrectomy)

Study Sites (1)

Loading locations...

Similar Trials